Global enteral nutrition market projected to grow from USD 9.2 billion in 2026 to USD 16.67 billion by 2036 at a 6.1% CAGR, according to Future Market Insights
The global Enteral Nutrition Market is projected to reach USD 16.67 billion by 2036, up from approximately USD 9.2 billion in 2026, expanding at a 6.1% CAGR during the forecast period, according to the latest analysis by Future Market Insights (FMI).
The market was valued at USD 8.69 billion in 2025 and is expected to create an incremental opportunity of USD 7.45 billion between 2026 and 2036. Growth is being supported by hospital procurement, expansion of home enteral nutrition, increasing demand for disease-specific formulas and broader adoption of clinical nutrition across healthcare settings.
Enteral nutrition comprises liquid and powdered nutritional formulas delivered through feeding tubes to patients unable to obtain adequate nutrition orally. The market includes standard polymer-based formulas, elemental and peptide-based formulas, disease-specific products, and specialty pediatric and adult nutrition products used across hospital, post-acute and home healthcare settings.
Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-19760
Standard Formulas Continue to Anchor the Market
Standard enteral formulas are expected to account for 50.0% of the product segment in 2026, maintaining their position as the largest product category.
Their widespread use across intensive care, acute care and long-term care settings supports continued demand. Standard formulas also provide a cost-effective option compared with disease-specific and other specialty formulations.
Polymer-based products remain the most common form of enteral nutrition. Abbott Laboratories’ Jevity, Nestle Health Science’s Isosource, Nutricia’s Nutrison and Fresenius Kabi’s Fresubin are identified in the FMI analysis as category-defining standard polymer-based formulas.
Disease-specific formulas represent an expanding premium segment, particularly across diabetes, renal and oncology applications.
Gastrointestinal Disorders Lead Applications
The gastrointestinal disorders segment is projected to account for 40.0% of application demand in 2026.
Short bowel syndrome, inflammatory bowel disease and pancreatic insufficiency are among the major applications within this segment. Oncology nutrition, neurological disorders and critical care also represent significant areas of enteral nutrition use.
The broad application base reflects the role of enteral nutrition in hospital treatment as well as longer-term patient care.
Hospitals Remain the Largest End-Use Segment
Hospitals are expected to account for 60.0% of end-use demand in 2026. Large-scale institutional procurement, intensive care requirements and inpatient treatment programs support the channel’s continued importance.
At the same time, the market is extending beyond traditional hospital settings.
Home enteral nutrition increased from less than 20% of category volume in 2015 to more than 30% in 2025, according to the supplied FMI analysis. The shift reflects demand for longer-term nutrition support outside hospitals and the role of home care in managing ongoing patient needs.
Disease-Specific Nutrition Creates Premium Opportunities
Disease-specific formulations are becoming increasingly relevant as healthcare providers seek nutrition solutions tailored to particular clinical conditions.
The report identifies diabetes-specific products such as Glucerna and Diasip, renal formulations including Nepro and Suplena, and specialty immune-modulating and peptide-based formulas.
According to the supplied analysis, disease-specific formulas command 40% to 60% price premiums over standard polymer-based formulas. This creates a distinct premium segment alongside the mainstream standard-formula market.
Reimbursement Remains a Market Consideration
Market expansion is also influenced by reimbursement coverage. Medicare, Medicaid and international payer policies affect access to home enteral nutrition depending on patient diagnosis and care setting.
Hospital formulary standardization can place pressure on branded pricing, while parenteral nutrition remains an alternative for patients who cannot tolerate enteral feeding.
For suppliers, established hospital relationships, regulatory compliance, clinical evidence and distribution capabilities remain relevant to market participation.
India and China Show Strong Growth
FMI’s country-level analysis identifies India as the fastest-growing market among the highlighted countries, with a projected 7.2% CAGR through 2036, followed by China at 6.7%.
Germany is projected to grow at 6.4%, Japan at 5.9%, and the United States at 5.8% during the forecast period.
India’s growth is associated in the report with expanding hospital infrastructure, increasing ICU capacity and growth in home healthcare. China’s market expansion is linked to hospital system development, aging demographics and increasing demand for premium clinical nutrition.
Competitive Landscape
The Enteral Nutrition Market is characterized by multinational medical nutrition companies and specialized clinical nutrition suppliers.
Key companies profiled by FMI include Abbott Laboratories, Nestle Health Science, Danone Nutricia, Fresenius Kabi, B. Braun SE, Baxter International, Otsuka Pharmaceutical, Pfrimmer Nutricia, Mead Johnson Nutrition and Hormel Health Labs.
Competitive positioning is influenced by hospital formulary access, formula portfolio breadth, clinical trial investment, manufacturing capabilities, reimbursement access and geographic distribution.
Analyst Perspective
“Companies that can align clinical efficacy with cost-effective delivery models are likely to strengthen their position in the evolving enteral nutrition market.”— Nandini Roy Choudhury, Principal Consultant, Future Market Insights
Exclusive Discounts on Full Report: https://www.futuremarketinsights.com/reports/enteral-nutrition-market
Report Scope
The FMI study covers the Enteral Nutrition Market by product, application, end use, distribution channel, formulation and pricing tier.
Product categories include standard enteral formulas, semi-elemental formulas, elemental formulas, disease-specific formulas and critical care formulas. Applications include gastrointestinal disorders, oncology nutrition, neurological disorders, critical care and geriatric nutrition.
The research covers North America, Latin America, Europe, East Asia, South Asia and Pacific, and the Middle East and Africa. The forecast period extends from 2026 to 2036.
FMI’s methodology combines primary research with desk research and market sizing. Analysts gathered input from procurement leaders, technical specialists and commercial managers across the value chain, while industry statistics, regulatory filings, company reports and trade publications were used to establish baseline parameters.
Key Executive Benefits
- Decision-Ready Insights
- Reduced Strategic Risk
- Market Entry Confidence
- Competitive Advantage
- Faster Growth Decisions
- Primary Market Validation.
To explore how FMI Custom Research can support your strategic priorities, connect with our team at – [email protected]
About Future Market Insights (FMI)
Future Market Insights, Inc. is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization trusted by Fortune 500 companies. With a global presence across the U.S., UK, India, and Dubai, FMI delivers data-driven insights across 30+ industries and 1200 markets worldwide.
